Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFIC-4/RTOG-3515: durvalumab or placebo with SBRT, plus an osimertinib EGFR-mutant cohort, in unresected stage I/II node-negative NSCLC
2024-512667-31-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Jun 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab + SBRT, Placebo + SBRT and Osimertinib cohort after SBRT (3 arms). Primary endpoints: Progression-free survival and 4-year progression-free survival. Planned start Jun 2024; status: authorised.
02
Drugs
durvalumabosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-512667-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512667-31-00.